Your session is about to expire
← Back to Search
Paricalcitol + Chemotherapy for Pancreatic Cancer
Study Summary
This trial is testing the safety and effectiveness of adding paricalcitol to gemcitabine and nab-paclitaxel in people with previously untreated, metastatic pancreatic cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2010 Phase 4 trial • 109 Patients • NCT01265615Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have high calcium levels in my blood.I have had painful kidney or bladder stones in the last year.I have severe nerve pain or numbness.I do not have any unmanaged ongoing illnesses.I can swallow and absorb pills.I am 18 years old or older.I am allergic to medications similar to paricalcitol, gemcitabine, or nab-paclitaxel.My cancer is a type of pancreatic cancer that has spread to distant parts of my body.It has been over 4 weeks since my last major surgery or open biopsy.I have had cancer before, but it meets certain conditions.I am fully active and can carry on all my pre-disease activities without restriction.I am not taking any drugs that affect the CYP450 3A enzyme.You need to have a specific amount of disease that can be measured according to certain standards.I am not pregnant.My organ and bone marrow functions are normal.I am not using any other cancer treatments.I have brain metastases.I have had chemotherapy or experimental treatments for advanced pancreatic cancer.I regularly take water pills for my blood pressure or swelling.I finished my post-surgery cancer treatment over a year ago.
- Group 1: Gemcitabine + Nab-paclitaxel + Placebo
- Group 2: Gemcitabine + Nab-paclitaxel + Paricalcitol IV
- Group 3: Gemcitabine + Nab-paclitaxel + Paricalcitol oral
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are patients still being accepted for this clinical research program?
"This study, which was last updated on October 24th 2022 and was first posted December 5th 2018, is not currently looking for patients. However, 1893 other studies are presently recruiting patients."
How many people are part of this experiment?
"Right now, this trial does not have any open positions. However, it is still an active study; the first posting was on December 5th, 2018 and the most recent edit was on October 24th, 2022. If you are interested in other studies, there are 726 trials for cancer of the pancreas and 1167 for Paricalcitol that are actively recruiting participants."
What are the most common illnesses that Paricalcitol is used to manage?
"Paricalcitol is commonly used as a treatment for neoplasm metastasis. Additionally, it has shown efficacy in treating locally advanced non-small cell lung cancer, metastatic bladder cancer, and urinary bladder."
What other medical studies involving Paricalcitol have been completed?
"Paricalcitol was first studied in 1997 and there have been over 2000 completed clinical trials involving this medication. Currently, 1167 studies are recruiting patients with a large number of these based out of Boston, Massachusetts."
Share this study with friends
Copy Link
Messenger